Item 1.01 Entry into a Material Definitive Agreement
First Amendment to Huadong License Agreement
On January 14, 2021, vTv Therapeutics LLC ("vTv LLC"), a subsidiary of vTv
Therapeutics Inc., entered into the First Amendment to License Agreement with
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. ("Huadong") (the "First
Amendment") to amend the License Agreement previously entered into between vTv
LLC and Huadong on December 21, 2017 (the "Original Agreement"). The First
Amendment eliminates vTv LLC's obligation to sponsor a Phase 2 Multi-Region
Clinical Trial and corresponding obligation to contribute up to $3.0 million in
support of such trial. The First Amendment also reduces the total potential
development and regulatory milestone payments of $25.0 million under the
Original Agreement by $3.0 million.
The foregoing description of the License Amendment is qualified in its entirety
by reference to the First Amendment, which the Company intends to file with the
SEC as an exhibit to the Company's Annual Report on Form 10-K for the year ended
December 31, 2020.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses